论文部分内容阅读
新药研发是一项投资大、周期长、风险高的工作,我国医药企业只有利用自身的优势和政策的推动,才能缩小与国外企业新药研发水平的差距。
R & D of new drugs is a big investment, long cycle and high risk work. Only by using their own advantages and policies to promote our pharmaceutical companies can we narrow the gap with the R & D level of new drugs in foreign companies.